ZA202204777B - Novel combinations for antigen based therapy - Google Patents

Novel combinations for antigen based therapy

Info

Publication number
ZA202204777B
ZA202204777B ZA2022/04777A ZA202204777A ZA202204777B ZA 202204777 B ZA202204777 B ZA 202204777B ZA 2022/04777 A ZA2022/04777 A ZA 2022/04777A ZA 202204777 A ZA202204777 A ZA 202204777A ZA 202204777 B ZA202204777 B ZA 202204777B
Authority
ZA
South Africa
Prior art keywords
composition
beta cell
antigen
vitamin
cell autoantigen
Prior art date
Application number
ZA2022/04777A
Other languages
English (en)
Inventor
Anders Essen-Möller
Johnny Ludvigsson
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of ZA202204777B publication Critical patent/ZA202204777B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2022/04777A 2014-06-04 2022-04-29 Novel combinations for antigen based therapy ZA202204777B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450678 2014-06-04
SE1451315 2014-11-04

Publications (1)

Publication Number Publication Date
ZA202204777B true ZA202204777B (en) 2024-09-25

Family

ID=54767532

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/04777A ZA202204777B (en) 2014-06-04 2022-04-29 Novel combinations for antigen based therapy

Country Status (20)

Country Link
US (3) US20170196949A1 (enExample)
EP (2) EP3760224A3 (enExample)
JP (2) JP6686007B2 (enExample)
CN (2) CN106535926B (enExample)
AU (3) AU2015268960B2 (enExample)
CA (2) CA2950893C (enExample)
CY (1) CY1123160T1 (enExample)
DK (1) DK3151853T3 (enExample)
ES (1) ES2807787T3 (enExample)
HU (1) HUE051151T2 (enExample)
IL (3) IL300130B2 (enExample)
LT (1) LT3151853T (enExample)
PL (1) PL3151853T3 (enExample)
PT (1) PT3151853T (enExample)
RS (1) RS60581B1 (enExample)
RU (1) RU2702632C2 (enExample)
SI (1) SI3151853T1 (enExample)
SM (1) SMT202000384T1 (enExample)
WO (1) WO2015187087A2 (enExample)
ZA (1) ZA202204777B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
EP4300102A3 (en) 2017-09-08 2024-01-24 Diamyd Medical AB Improved immunotherapy
JP7337780B2 (ja) * 2017-09-08 2023-09-04 ダイアミド・メディカル・アクチボラゲット 糖尿病の処置および予防における遺伝子型層別化
EP3749354A4 (en) * 2018-02-05 2021-11-03 Diamyd Medical AB NEW COMPOSITION AND ITS USE
EP3761988A4 (en) * 2018-03-07 2021-12-29 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
US10500217B2 (en) * 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
WO2020210798A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
KR20230109676A (ko) * 2020-11-16 2023-07-20 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 지방산 입자가 없는 제형, 방법, 및 사전 충전형 주사 장치
WO2022155188A1 (en) * 2021-01-13 2022-07-21 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
KR19990063648A (ko) * 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
IL162077A0 (en) * 2001-11-21 2005-11-20 Univ Leland Stanford Junior Polynucleotide therapy the board of trustees of the leland stanford junior university
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
JP2009511014A (ja) * 2005-10-05 2009-03-19 ベイヒル セラピューティクス インコーポレーティッド 自己免疫疾患の処置のための組成物および方法
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
EP3269384A1 (en) * 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
KR20100022022A (ko) * 2007-04-24 2010-02-26 다이아미드 쎄라퓨틱스 아베 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
EP2394657A1 (en) * 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009078796A1 (en) * 2007-12-19 2009-06-25 Mivac Development Aktiebolag Compositions and methods for treatment of autoimmune and allergic diseases
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Also Published As

Publication number Publication date
RU2019129803A (ru) 2020-12-14
IL300130B1 (en) 2024-01-01
EP3151853A2 (en) 2017-04-12
IL249250B (en) 2020-03-31
RU2016150656A (ru) 2018-07-10
JP6686007B2 (ja) 2020-04-22
AU2015268960A1 (en) 2016-12-15
JP2017516870A (ja) 2017-06-22
WO2015187087A3 (en) 2016-01-28
PT3151853T (pt) 2020-07-27
CA2950893A1 (en) 2015-12-10
RS60581B1 (sr) 2020-08-31
EP3151853B1 (en) 2020-05-06
SI3151853T1 (sl) 2020-10-30
AU2022202003A1 (en) 2022-04-14
CY1123160T1 (el) 2021-10-29
AU2022202003B2 (en) 2024-12-12
CN114504639A (zh) 2022-05-17
WO2015187087A2 (en) 2015-12-10
AU2020203169B2 (en) 2021-12-23
US20220000995A1 (en) 2022-01-06
AU2020203169A1 (en) 2020-06-04
IL300130A (en) 2023-03-01
JP2020125300A (ja) 2020-08-20
HUE051151T2 (hu) 2021-03-01
CA3210184A1 (en) 2015-12-10
SMT202000384T1 (it) 2020-09-10
IL273265B2 (en) 2023-06-01
IL300130B2 (en) 2024-05-01
RU2702632C2 (ru) 2019-10-09
RU2016150656A3 (enExample) 2019-01-25
US20240299514A1 (en) 2024-09-12
LT3151853T (lt) 2020-08-10
AU2015268960B2 (en) 2020-04-09
IL273265A (en) 2020-04-30
CN106535926A (zh) 2017-03-22
CA2950893C (en) 2023-10-10
EP3760224A2 (en) 2021-01-06
US20170196949A1 (en) 2017-07-13
EP3760224A3 (en) 2021-03-31
CN106535926B (zh) 2022-02-01
PL3151853T3 (pl) 2020-11-02
IL249250A0 (en) 2017-02-28
EP3151853A4 (en) 2018-04-25
DK3151853T3 (da) 2020-07-27
ES2807787T3 (es) 2021-02-24

Similar Documents

Publication Publication Date Title
ZA202204777B (en) Novel combinations for antigen based therapy
Zhou et al. 1, 25-Dihydroxyvitamin D3 ameliorates collagen-induced arthritis via suppression of Th17 cells through miR-124 mediated inhibition of IL-6 signaling
Schroeder et al. The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia
Hill et al. Glycogen synthase kinase‐3 controls IL‐10 expression in CD4+ effector T‐cell subsets through epigenetic modification of the IL‐10 promoter
Beres et al. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease
Nijhuis et al. Adrenergic β2 receptor activation stimulates anti-inflammatory properties of dendritic cells in vitro
Napolitani et al. Prostaglandin E2 enhances Th17 responses via modulation of IL‐17 and IFN‐γ production by memory CD4+ T cells
Lee et al. Progesterone suppresses the m TOR pathway and promotes generation of induced regulatory T cells with increased stability
Saouaf et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis
Tvedt et al. Interleukin-6 in allogeneic stem cell transplantation: its possible importance for immunoregulation and as a therapeutic target
Nair et al. DNA demethylation of the Foxp3 enhancer is maintained through modulation of ten-eleven-translocation and DNA methyltransferases
EP3119913A2 (en) Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
Dubrot et al. Absence of MHC-II expression by lymph node stromal cells results in autoimmunity
Baharlou et al. Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells activation
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
Guo et al. The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura
EP4545143A3 (en) Early intervention methods to prevent or ameliorate toxicity
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CN110088623A (zh) 选择用于治疗免疫病症的高效干细胞的方法
EP4219690A3 (en) Methods of cancer treatment using activated t cells
Wang et al. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis
JP2017521485A (ja) ガレクチン−９に対して方向づけられ、制御性ｔリンパ球の抑制活性の阻害剤である抗体
CO6612271A2 (es) Anticuerpos anti-cd40
Wang et al. Methylprednisolone alleviates multiple sclerosis by expanding myeloid‐derived suppressor cells via glucocorticoid receptor β and S100A8/9 up‐regulation